Immune Pharmaceuticals Inc

Immune Pharmaceuticals — Investor Presentation (March 2015)

23 slides from Immune Pharmaceuticals's investor presentation, Mar 11, 2015

  1. Slide 1: Investor Presentation March 2015

    Investor Presentation March 2015

  2. Slide 2: Forward-Looking Statement

    Forward - Looking Statement This presentation and any oral statements made with respect to the information contained in this presentation contain forward - looking statements that involve risks and uncertainties regarding the operations and future results of Immune Pharmaceuticals, Inc . You are urg

  3. Slide 3: Corporate Highlights

  4. Slide 4: Immune Pharmaceuticals Corporate Overview

    Immune Pharmaceuticals (NASDAQ:IMNP) Corporate Overview Leadership Team in New York City • NASDAQ listed company (IMNP) • First in Class Phase 2 Biologic candidate, Bertilimumab, for Auto - Immune Diseases ▪ Targeted Personalized Antibody Therapeutic with Companion Diagnostic opportunity ▪ Focus on

  5. Slide 5: Our Goal Is to Transform Targeted Immunotherapy

    ▪ Personalized Medicine based on patient selection and targeted therapy ▪ Bertilimumab : First in Class fully H uman mAb originally developed by CAT (now part of AZ ) to improve the lives of patients with Severe Inflammatory and/ or Auto - Immune Diseases due to Eotaxin - 1 over expression including

  6. Slide 6: Clinical Stage Portfolio With Multiple Shots on Goal

    Clinical Stage Portfolio With Multiple Shots on Goal Resources Prioritized For Bertilimumab Phase II BP And UC Trials PROGRAMS Preclinical Phase 1 Phase 2 Phase 3 I NFLAMMATION Bertilimumab Bullous Pemphigoid IBD (Crohn’s and Colitis) Severe Asthma NASH A NTIBODY NANOPARTICLE CONJUGATES NanomAbs® (p

  7. Slide 7: Highly Experienced Leadership Team

    Highly Experienced Leadership Team Management Daniel Teper, PharmD, MBA Founder & CEO and Director ; Novartis, GSK, Sanofi, Bionest Gad Berdugo, Msc, MBA EVP and Chief Financial Officer ; Abbott, Baxter, Lazard, Tegris Paul Nadler, MD, PhD EVP, R&D and Chief Medical Officer; National Cancer Institut

  8. Slide 8: Bertilimumab

    Bertilimui Changing the outco diseases through biomarke flammatory ased patient selection OP IMMUNE

  9. Slide 9: Eotaxin-1 Is Upregulated In Patients With Inflammatory Diseases

    Eotaxin - 1 Is Upregulated In Patients With Inflammatory Diseases in Multiple Organs 9 Bullous Pemphigoid Crohn’s Disease/Ulcerative Colitis Non Alcoholic Steato - hepatitis(NASH ). Severe Asthma

  10. Slide 10: Bertilimumab may reach $1.1B in US/EU sales in Bullous Pemphigoid

    Bertilimumab may reach $ 1.1 B* in US/EU sales in Bullous Pemphigoid Prevalence (# of patients) US/EU Market size currently estimated at 60,000 patients, expected to reach 90,000 by 2025 due to population aging and increased diagnosis Initial target price for bertilimumab in Bullous Pemphigoid proje

  11. Slide 11: Eosinophils are Predominant in the BP Inflammatory Process

    Eosinophils are Predominant in the BP Inflammatory Process Bertilimumab Neutralizes Eotaxin - 1 , a Key Regulator of Eosinophils 11 Significant unmet need for targeted therapy with improved safety profile SOURCE: Dr. Neil Kormin, Case Western

  12. Slide 12: Bertilimumab Targets Bullous Pemphigoid, an Autoimmune Orphan Disease

    Bertilimumab Targets Bullous Pemphigoid, an Autoimmune Dermatological Orphan Disease 12 SOURCE: IPPF - Internatioal Pemphigus Pemphigoid Foundation - database, P/P Patient Registry, and independent study Rare autoimmune skin blistering Disease Aging orphan disease Estimated population of 60,000 in t

  13. Slide 13: Positive Preclinical Efficacy In Dermal Inflammation Model

    Bertilimumab: Positive Preclinical Efficacy In Dermal Inflammation Model (A) total cell and (B) eosinophil recruitment to the perivascular dermis Bertilimumab efficacy was evaluated in monkey inflammatory dermis Study included 16 cynomolgus monkeys, assigned to 3 different treatment groups Bertilimu

  14. Slide 14: Inflammatory Bowel Disease Opportunity

    ▪ Over 3 million sufferers g lobally, 50 % showing high eotaxin 1 level ▪ Anti TNF sell over $ 4 B in moderate to severe inflammatory bowels diseases but show limitations with loss of efficacy after 1 year ▪ Entivyo (Takeda) was approved in 2014 as first line biologic and opens the market for more t

  15. Slide 15: Eotaxin-1 is up-regulated in Patients with liver diseases including NASH

    Eotaxin - 1 is up - regulated in Patients with liver diseases including NASH Eotaxin - 1 plasma levels are elevated in subjects with liver inflammatory diseases such as Non Alcoholic Steato - hepatitis (NASH). Plasma Eotaxin - 1 could be seen as a potential early biomarker in NASH In obese subjects

  16. Slide 16: Recent Publications Linking Eotaxin with Inflammatory Liver Disease

    Recent Publications in Leading Journals Linking Eotaxin - 1 with Inflammatory Liver Disease, Obesity, Cardiovascular Disease, Insulin Resistance and Diabetes Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis Eosi

  17. Slide 17: AmiKet: Phase III ready product for Neuropathic Pain

    opathic Pain, es Phase III ready product for Neur positioned for out Uy IMMUNE

  18. Slide 18: AmiKet: Significant Short Term Monetization Opportunity

    AmiKet: Significant Short Term Monetization Opportunity Advanced Partnering Discussions Ongoing • AmiKet is a topical formulation of amitriptyline and ketamine that has completed Phase II clinical trails in neuropathic pain. AmiKet has clinical evidence of potential efficacy and safety in 1,700 subj

  19. Slide 19: AmiKet Non-Inferior to Gabapentin HD in PHN

    AmiKet Non - Inferior to Gabapentin HD in Post Herpetic Neuralgia (PHN) 0 1 2 3 4 5 6 7 Placebo n=76 Amiket n=135 Gabapentin n=138 Baseline End of Week 4 Mean Pain Score p = 0.044 p = 0.84

  20. Slide 20: Physicians Express Strong Demand For a Highly Effective Topical Drug

    Physicians Express Strong Demand For a Highly Effective Topical Drug Source: Interviews The main advantage of AmiKet is that it is not a systemic drug, and would prescribe it as a monotherapy for many of my patients … ” - EU Pain Specialist, Ambroise Pare Hospital ( France) “… Since a topical treatm

  21. Slide 21: NanomAb ADC 2.0

    NANOMA ADC 2.0 TARGETED NANOPA FOR IMPROVED CANCER THERAPY OUTCOMES OP IMMUNE

  22. Slide 22: NanomAbs: ADC 2.0 May Optimize the Efficacy/Safety Ratio

    Existing and Novel mAb targets with strong internalization properties HER 2 , EGFR, H - Ferritin, Others High Payload: Up to 20,000 molecules per nanoparticle Versatility of drugs to be delivered , not limited to toxins , Triple Targeting : Tumor Targeting, Cellular Targeting, Molecular Targeting Ta

  23. Slide 23: 2015 Milestones / Stock Catalysts

    2015 Milestones / Stock Catalysts Quarter 2 Quarter 3 Quarter 4 Partnering of AMIKET Q 2 2015 Initiation of Amiket NP development Q 2 2015 First Patient in BP Phase II Study with Bertilimumab Q 2 2015 Orphan Drug designation for Bertilimumab in BP Q 3 2015 First Patient in UC phase II study with Ber

Immune Pharmaceuticals — Investor Presentation (March 2015) on 6ix